Teva Pharmaceutical Industries Pre-Tax Profit Margin 2010-2024 | TEVA

Current and historical pre-tax profit margin for Teva Pharmaceutical Industries (TEVA) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Teva Pharmaceutical Industries pre-tax profit margin for the three months ending June 30, 2024 was .
Teva Pharmaceutical Industries Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2024-06-30 $16.29B $-0.14B -0.87%
2024-03-31 $16.00B $-0.82B -5.12%
2023-12-31 $15.85B $-0.62B -3.94%
2023-09-30 $15.27B $-2.32B -15.18%
2023-06-30 $15.02B $-2.23B -14.83%
2023-03-31 $14.93B $-2.46B -16.51%
2022-12-31 $14.93B $-3.16B -21.19%
2022-09-30 $15.14B $-2.14B -14.14%
2022-06-30 $15.43B $-1.93B -12.47%
2022-03-31 $15.56B $-0.46B -2.94%
2021-12-31 $15.88B $0.66B 4.14%
2021-09-30 $16.23B $0.97B 5.98%
2021-06-30 $16.32B $-3.87B -23.71%
2021-03-31 $16.28B $-4.23B -25.97%
2020-12-31 $16.66B $-4.41B -26.45%
2020-09-30 $16.67B $-4.58B -27.48%
2020-06-30 $16.79B $-0.42B -2.47%
2020-03-31 $17.10B $-1.21B -7.10%
2019-12-31 $16.89B $-1.27B -7.49%
2019-09-30 $16.40B $-4.61B -28.14%
2019-06-30 $16.83B $-4.53B -26.94%
2019-03-31 $17.36B $-3.93B -22.67%
2018-12-31 $18.27B $-2.60B -14.21%
2018-09-30 $19.69B $-12.42B -63.05%
2018-06-30 $20.78B $-12.09B -58.15%
2018-03-31 $21.80B $-17.81B -81.71%
2017-12-31 $22.39B $-18.38B -82.10%
2017-09-30 $23.48B $-6.09B -25.92%
2017-06-30 $23.43B $-5.59B -23.86%
2017-03-31 $22.74B $0.65B 2.84%
2016-12-31 $21.90B $0.82B 3.76%
2016-09-30 $20.29B $2.60B 12.81%
2016-06-30 $19.55B $2.30B 11.75%
2016-03-31 $19.48B $2.66B 13.67%
2015-12-31 $19.65B $2.35B 11.97%
2015-09-30 $19.94B $2.36B 11.85%
2015-06-30 $20.17B $3.08B 15.26%
2015-03-31 $20.25B $3.30B 16.31%
2014-12-31 $20.27B $3.64B 17.95%
2014-09-30 $20.53B $3.27B 15.91%
2014-06-30 $20.54B $2.96B 14.43%
2014-03-31 $20.41B $1.44B 7.06%
2013-12-31 $20.31B $1.25B 6.15%
2013-09-30 $20.13B $0.93B 4.63%
2013-06-30 $20.05B $0.08B 0.37%
2013-03-31 $20.12B $1.66B 8.25%
2012-12-31 $20.32B $1.82B 8.95%
2012-09-30 $20.74B $2.18B 10.49%
2012-06-30 $20.12B $3.28B 16.30%
2012-03-31 $19.33B $2.99B 15.44%
2011-12-31 $18.31B $2.96B 16.14%
2011-09-30 $17.05B $3.14B 18.42%
2011-06-30 $16.96B $3.36B 19.80%
2011-03-31 $16.55B $3.67B 22.17%
2010-12-31 $16.12B $3.65B 22.62%
2010-09-30 $15.51B $3.31B 21.32%
2010-06-30 $14.81B $2.82B 19.05%
2010-03-31 $14.41B $2.54B 17.60%
2009-12-31 $13.90B $2.20B 15.85%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $20.902B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Personalis (PSNL) United States $0.270B 0.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00